Thoughts of the safety and efficacy of EUS-guided cyst ablation with the use of lauromacrogol

We read with interest the clinical trial by Linghu et al1 investigating the safety and effectiveness of lauromacrogol for EUS-guided ablation of pancreatic cystic neoplasms. The authors reported an adverse event (AE) rate of 8.3% and an overall complete response rate of 37%. They concluded that this approach as safe and efficient. We have a few thoughts, which may be helpful.

https://ift.tt/2EFnS4n